Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital for Research and Treatment, recently shared on LinkedIn:

“Being the last speaker after 2 days of exhausting discussions and interactive workshops at the International Medical Conference is a challenge, but usually, your exciting subject and professional presentation can make your job easier.

This is what I have learned from Harvard Training to Teach ( Medical School course training to teach).

Yesterday was my presentation in Onco Azhar about (maintenance immunotherapy
avelumab after induction chemotherapy for advanced TCC bladder cancer).

Although it was the last presentation after exhausting scientific Oncology meetings, most of the audience was really exhausted, but at the same time, excited about the subject: as they discussed all aspects of advanced urinary bladder carcinoma from epidemiology, treatment up to maintenance therapy and its cost benefit.
We discussed subgroup analyses of Javelin bladder 100: most of the oncologists were excited to know that even patients who reached CR after chemotherapy, good benefit from maintenance therapy by avelumab.
In the end, we asked ourselves: Can poor Egyptian patients really have this benefit of OS?
We beed real world data from Egypt.
But unfortunately there’s a little number of patients receiving this treatment: maintenance avelumab because of its high cost.”

Source: Rasha Aboelhassan/LinkedIn